Harrow, Inc.

HROW

US4158581094

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 18:43:28 09/03/2026 +04			5-day change	1st Jan Change
34.52 ^USD	-5.05%		-35.78%	-29.76%

03-03	Top Midday Decliners	MT
03-03	Harrow, Inc., Q4 2025 Earnings Call, Mar 03, 2026

Harrow to initiate phase 3 clinical trial seeking to expand Triesence® label to include ocular inflammation and pain following cataract surgery indication

Published on 03/03/2026 at 04:49 pm +04

Reuters

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Harrow, Inc.

03-03	Top Midday Decliners	MT
03-03	Harrow, Inc., Q4 2025 Earnings Call, Mar 03, 2026
03-03	Harrow Initiates Phase 3 Clinical Trial To Expand Triesence Label For Ocular Inflammation And Pain Following Cataract Surgery	CI
03-03	Harrow to initiate phase 3 clinical trial seeking to expand Triesence® label to include ocular inflammation and pain following cataract surgery indication	RE
03-03	Harrow Says US FDA Clears Phase 3 Trial of Triesence in Post-Cataract Surgery Pain	MT
03-03	Earnings Flash (HROW) Harrow Posts Q4 EPS $0.17, vs. FactSet Est of $0.37	MT
03-03	Harrow Q4 Earnings Fall, Revenue Rises	MT
03-03	Earnings Flash (HROW) Harrow, Inc. Reports Q4 Revenue $89.1M, vs. FactSet Est of $90.0M	MT
03-03	Harrow, Inc. Provides Earnings Guidance for the First Half, Second Half and Full Year of 2026	CI
03-03	Harrow, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
02-17	Harrow, Inc. Announces Cash-Pay Direct-To-Prescriber Pharmapack?? Kits	CI
02-02	Harrow, Inc. Promotes Patrick W. Sullivan as Chief Commercial Officer, Effective January 30, 2026	CI
02-02	Harrow, Inc. Reaffirms Its Full-Year 2025 Revenue Guidance	CI
02-02	(HROW) Harrow Expects 2025 Revenue Range $270M - $280M, vs. FactSet Est of $273.4M	MT
11-18	Harrow Closes Melt Pharmaceuticals Acquisition	MT

Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

Employees

373

Sector

Pharmaceuticals

More about the company